Cargando…
SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers
Immune checkpoint inhibitors (ICIs) have transformed the management of advanced cancers. However, many patients could not benefit from ICIs therapy, and thus several biomarkers for therapeutic prediction have been uncovered. In this research, more than ten public and in-house cohorts were used to ex...
Autores principales: | Mei, Jie, Fu, Ziyi, Cai, Yun, Song, Chenghu, Zhou, Jiaofeng, Zhu, Yichao, Mao, Wenjun, Xu, Junying, Yin, Yongmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932126/ https://www.ncbi.nlm.nih.gov/pubmed/36818292 http://dx.doi.org/10.1016/j.isci.2023.106027 |
Ejemplares similares
-
SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers
por: Mei, Jie, et al.
Publicado: (2023) -
HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
por: Mei, Jie, et al.
Publicado: (2022) -
GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC
por: Fan, Honghong, et al.
Publicado: (2023) -
GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer
por: Mei, Jie, et al.
Publicado: (2023) -
Tex19 and Sectm1 concordant molecular phylogenies support co-evolution of both eutherian-specific genes
por: Bianchetti, Laurent, et al.
Publicado: (2015)